أعرض في EDS

752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations

التفاصيل البيبلوغرافية
العنوان: 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
المؤلفون: Luc Dirix, Remy Delva, Victor Moreno, A.P. Lykov, Begoña Mellado, Y. Loriot, Sergei Varlamov, Arlene O. Siefker-Radtke, Sydney Akapame, A. Semenov, Salvatore Siena, S. Mosher, Carmen Beato, Anne OHagan, Ignacio Duran, M.A. Climent Duran, Scott T. Tagawa, T.W. Kang, M. Tammaro, Lionnel Geoffrois
المصدر: Annals of Oncology. 31:S584-S585
بيانات النشر: Elsevier BV, 2020.
سنة النشر: 2020
مصطلحات موضوعية: Oncology, Erdafitinib, Fibroblast growth factor receptor, business.industry, Locally advanced, Cancer research, Medicine, In patient, Hematology, business, Urothelial carcinoma
تدمد: 0923-7534
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d37c1d3789ec821e6aaa547c6282f880
https://doi.org/10.1016/j.annonc.2020.08.824
حقوق: OPEN
رقم الأكسشن: edsair.doi...........d37c1d3789ec821e6aaa547c6282f880
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09237534